Akathisia and an unusual symptomatic treatment: A case report

Palliative Medicine

Volumn 21, Issue 8, 2007, Pages 713-715

  Back, Ian ^a   Taubert, Mark ^b  

^a Hamad Medical Coorporation Doha Qatar   (United Kingdom)

^b MORRISTON HOSPITAL   (United Kingdom)

Author keywords

Akathisia; Exercise; Fluoxetine; Haloperidol; Restlessness

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIZINE; FLUOXETINE; HALOPERIDOL; LEVOMEPROMAZINE; OXYCODONE;

ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; CACHEXIA; CANCER FATIGUE; CANCER PALLIATIVE THERAPY; CASE REPORT; CONVALESCENCE; DAILY LIFE ACTIVITY; DEPRESSION; DISEASE SEVERITY; DISTRESS SYNDROME; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HOSPITAL ADMISSION; HUMAN; INTESTINE OBSTRUCTION; METASTASIS POTENTIAL; NAUSEA; OVARY CARCINOMA; PHYSIOTHERAPY; RESTLESSNESS; SYMPTOMATOLOGY; TREADMILL EXERCISE; VOMITING;

AKATHISIA, DRUG-INDUCED; CYCLIZINE; EXERCISE THERAPY; FEMALE; FLUOXETINE; HALOPERIDOL; HUMANS; METHOTRIMEPRAZINE; MIDDLE AGED; OVARIAN NEOPLASMS; OXYCODONE; PALLIATIVE CARE; TREATMENT OUTCOME;

EID: 38549092005     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: 10.1177/0269216307083598     Document Type: Article

References (24)

1. Hamilton MS, Opler LA. Akathisia, suicidality, and fluoxetine. J Clin Psychiatry 1992; 53(11): 401-6.
2. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 1998; 12(2): 192-214.
3. Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004; 161(1): 160-3.
4. Kim JH, Byun HJ. Prevalence and characteristics of subjective akathisia, objective akathisia, and mixed akathisia in chronic schizophrenic subjects. Clin Neuropharmacol 2003; 26(6): 312-6.
5. Gattera JA, Charles BG, Williams GM, Cavenagh JD, Smithurst BA, Luchjenbroers J. A retrospective study of risk factors of akathisia in terminally ill patients. J Pain Symptom Manage 1994; 9(7): 454-61.
6. Joint Formulary Committee. British national formulary, 51st edition. British Medical Association and Royal Pharmaceutical Society of Great Britain, 2006.
7. Holley FO, Magliozzi JR, Stanski DR, Lombrozo L, Hollister LE. Haloperidol kinetics after oral and intravenous doses. Clin Pharmacol Ther 1983; 33(4): 477-84.
8. Magliozzi JR, Hollister LE. Elimination half-life and bioavailability of haloperidol in schizophrenic patients. J Clin Psychiatry 1985; 46(1): 20-1.
9. Darby JK, Pasta DJ, Dabiri L, Clark L, Mosbacher D. Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 1995; 15(5): 334-40.
10. Froemming JS, Lam YW, Jann MW, Davis CM. pharmacokinetics of haloperidol. Clin Pharmacokinet 1989; 17(6): 396-423.
11. Caley CF. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother 1997; 31(12): 1481-9.
12. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 1996; 57(10): 449-54.
13. Lal S, Nair NP, Cecyre D, Quirion R. Levomepromazine receptor binding profile in human brain-implications for treatment-resistant schizophrenia. Acta Psychiatr Scand 1993; 87(6): 380-3.
14. Eisenchlas JH, Garrigue N, Junin M, De Simone GG. Low-dose levomepromazine in refractory emesis in advanced cancer patients: an open-label study. Palliat Med 2005; 19(1): 71-5.
15. Kennett A, Hardy J, Shah S, A'Hern R. An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer. Supp Care Cancer 2005; 13(9): 715-21.
16. Skinner J, Skinner A. Levomepromazine for nausea and vomiting in advanced cancer. Hosp Med 1999; 60(8): 568-70.
17. Hansen L. A critical review of akathisia, and its possible association with suicidal behaviour. Hum Psychopharmacol 2001; 16(7): 495-505.
18. Lima AR, Bacalcthuk J, Barnes TR, Soares-Weiser K. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2004; (4): CD001946.
19. Lima AR, Weiser KV, Bacaltchuk J, Barnes TR. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2004; (1): CD003727.
20. Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol 2003; 23(3): 305-8.
21. Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A Randomized, Double-Blind, Placebo- and Propranolol-Controlled Trial. Biol Psychiatry 2006; 59(11): 1071-7.
22. Ranjan S, Chandra PS, Chaturvedi SK, Prabhu SC, Gupta A. Atypical antipsychotic-induced akathisia with depression: therapeutic role of mirtazapine (April). Ann Pharmacother 2006; 40(4): 771-4.
23. He N, Zhang WQ, Shockley D, Edeki T. Inhibitory effects of H1-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes. Eur J Clin Pharmacol 2002; 57(12): 847-51.
24. Suzuki A, Yasui-Furukori N, Mihara K, Kondo T, Furukori H, Inoue Y, Kaneko S, Otani K. Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. There Drug Monit 2003; 25(2): 192-6.